Ryvu Therapeutics SA (PL:RVU)

:RVU

RVU

Ryvu Therapeutics SA

RESEARCH TOOLSreports

Want to see PL:RVU full AI Analyst Report?

Ryvu Therapeutics SA (RVU) Price & Analysis

0 Followers

RVU Stock Chart & Stats

zł27.65

Market closed

zł27.65

Day’s Range― - ―

52-Week Rangezł20.50 - zł33.30

Previous CloseN/A

VolumeN/A

Average Volume (3M)26.70K

Market Cap

zł523.67M

Enterprise Valuezł535.78M

Total Cash (Recent Filing)zł107.68M

Total Debt (Recent Filing)zł71.72M

Price to Earnings (P/E)―

Beta1.00

Next Earnings

Sep 10, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.45

Shares Outstanding23,120,148

10 Day Avg. Volume24,770

30 Day Avg. Volume26,695

Financial Highlights & Ratios

PEG Ratio0.68

Price to Book (P/B)11.64

Price to Sales (P/S)10.06

P/FCF Ratio-5.32

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-2.68

Revenue Forecast (FY)zł183.01M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthThe company's strong revenue growth rate indicates expanding operations and potential market capture, which is crucial for long-term sustainability in the competitive biotech industry.

Gross Profit MarginA strong gross profit margin suggests effective cost management and pricing power, which can support future profitability as the company scales its operations.

Cash Flow GrowthPositive free cash flow growth indicates improving cash generation ability, which is essential for funding R&D and supporting strategic initiatives without relying heavily on external financing.

Bears Say

Profitability ChallengesOngoing profitability issues highlight difficulties in converting revenue into net income, which could hinder long-term financial health and investment in growth opportunities.

Operating Cash FlowNegative operating cash flow suggests the company is not generating sufficient cash from its core operations, potentially limiting its ability to sustain growth and meet financial obligations.

Return On EquityNegative return on equity reflects inefficiencies in using shareholder funds to generate profits, which could deter investors and affect the company's ability to raise capital.

RVU FAQ

What was Ryvu Therapeutics SA’s price range in the past 12 months?

Ryvu Therapeutics SA lowest stock price was zł20.50 and its highest was zł33.30 in the past 12 months.

What is Ryvu Therapeutics SA’s market cap?

Ryvu Therapeutics SA’s market cap is zł523.67M.

When is Ryvu Therapeutics SA’s upcoming earnings report date?

Ryvu Therapeutics SA’s upcoming earnings report date is Sep 10, 2026 which is in 112 days.

How were Ryvu Therapeutics SA’s earnings last quarter?

Currently, no data Available

Is Ryvu Therapeutics SA overvalued?

According to Wall Street analysts Ryvu Therapeutics SA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Ryvu Therapeutics SA pay dividends?

Ryvu Therapeutics SA does not currently pay dividends.

What is Ryvu Therapeutics SA’s EPS estimate?

Ryvu Therapeutics SA’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ryvu Therapeutics SA have?

Ryvu Therapeutics SA has 23,120,148 shares outstanding.

What happened to Ryvu Therapeutics SA’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Ryvu Therapeutics SA?

Currently, no hedge funds are holding shares in PL:RVU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Ryvu Therapeutics SA

Ryvu Therapeutics S.A., a clinical stage biopharmaceutical company, engages in developing of novel small molecule therapies for treatment in oncology. Its lead candidate, RVU120, is a CDK8 kinase inhibitor with potential for development in hematological malignancies and solid tumors, which is in Phase 1b study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. The company's products also include SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group that is in Phase 2 clinical trial for the treatment of acute myeloid leukemia. In addition, its early pipeline candidates include candidates in the area of kinases, cancer metabolism, synthetic lethality, and immuno-oncology. Ryvu Therapeutics S.A. was founded in 2007 and is headquartered in Kraków, Poland.